Bioavailability In Structural Models

Bioavailability as a Dose-Input Parameter

A dose administered outside the vein does not necessarily reach the systemic circulation unchanged. The fraction that does is represented in a pharmacokinetic structural model by bioavailability. Including this fraction in the dose-input model separates the amount administered from the amount that becomes available to the disposition system. This distinction matters when comparing routes, formulations, or populations: a lower concentration profile may reflect less systemic input, not necessarily faster elimination.

For intravenous administration, the administered dose enters the systemic circulation directly, so absolute bioavailability is conventionally \(F=1\). For an extravascular dose, \(F\) is ordinarily between zero and one. It can reflect incomplete absorption and presystemic loss before unchanged drug reaches the systemic circulation. It is not, by itself, a measure of how quickly the drug is absorbed.

Definition: Absolute bioavailability, \(F\), is the fraction of an administered dose that reaches the systemic circulation as unchanged drug. In a structural model it multiplies systemic drug input. Relative bioavailability compares dose-normalized systemic exposure from a test formulation or route with that from a reference formulation or route. A relative bioavailability ratio can exceed one; it is not necessarily an absolute fraction.

To see the role of \(F\), consider a one-compartment model with first-order absorption from an oral depot. If the administered dose is \(D\), the depot amount is \(A_g(t)\), and the central amount is \(A_c(t)\), the input and disposition equations are

\frac{dA_g}{dt}=-k_a A_g,\qquad A_g(0)=D,

\frac{dA_c}{dt}=F k_a A_g-k_e A_c,\qquad C(t)=\frac{A_c(t)}{V}.

Here \(k_a\) is the first-order absorption rate constant, \(k_e\) is the first-order elimination rate constant, \(V\) is the apparent volume of distribution, and \(C(t)\) is concentration. The systemic input rate is \(F k_a A_g\): \(F\) scales the amount entering the systemic circulation, while \(k_a\) governs the rate at which the depot delivers its available amount.

Why Bioavailability Scales Exposure Under Linear PK

Under linear pharmacokinetics, disposition is proportional to concentration and does not change with dose over the range considered. Assume clearance \(CL\) is constant, the full concentration-time profile is observed or extrapolated appropriately, and all systemic drug entering the body is ultimately eliminated through clearance. For an extravascular dose, the total amount entering systemically is \(FD\). The total amount eliminated is \(CL\) multiplied by the area under the concentration-time curve (AUC). Equating these amounts gives the exposure relationship.

CL \cdot AUC_{\mathrm{extravascular}}=FD \qquad\Longrightarrow\qquad AUC_{\mathrm{extravascular}}=\frac{FD}{CL}.

For an intravenous dose, the corresponding relationship is \(AUC_{\mathrm{IV}}=D_{\mathrm{IV}}/CL\). Therefore, when the same linear disposition applies to both administrations, absolute bioavailability can be calculated from dose-normalized AUCs:

F= \frac{AUC_{\mathrm{extravascular}}/D_{\mathrm{extravascular}}} {AUC_{\mathrm{IV}}/D_{\mathrm{IV}}}.

The same reasoning applies to two extravascular formulations of the same drug. If the reference and test conditions share the same clearance and PK is linear, their relative bioavailability is

F_{\mathrm{rel}}= \frac{AUC_{\mathrm{test}}/D_{\mathrm{test}}} {AUC_{\mathrm{reference}}/D_{\mathrm{reference}}}.

These AUC ratios do not require the concentration-time profiles to have the same shape. They quantify dose-normalized exposure, not absorption rate. However, interpreting an AUC ratio as a bioavailability comparison depends on the shared-clearance and linearity assumptions.

Worked Example: Absolute Bioavailability From AUC

In a hypothetical study, a participant receives a 500 mg IV dose and, on a separate occasion, a 600 mg oral dose. The measured AUCs are 50 mg·h/L after IV dosing and 36 mg·h/L after oral dosing. Assume the same clearance on both occasions, linear PK at these doses, and AUC values that represent the complete exposure.

First calculate exposure per administered milligram for each route:

IV: \(50\ \text{mg·h/L} \div 500\ \text{mg}=0.1000\ \text{h/L}\). Oral: \(36\ \text{mg·h/L} \div 600\ \text{mg}=0.06000\ \text{h/L}\).

Then take the ratio:

F=\frac{0.06000\ \text{h/L}}{0.1000\ \text{h/L}}=0.6000.

The estimated absolute bioavailability is 0.600, or 60.0%. Under the stated assumptions, about 60% of the oral dose reaches the systemic circulation as unchanged drug. This estimate does not say that oral absorption occurs at 60% of the IV rate; it describes the fraction of dose reaching the systemic circulation.

Exposure Scale and Concentration-Time Shape

For the first-order oral model above, the depot solution is \(A_g(t)=D e^{-k_a t}\). When \(k_a\ne k_e\), solving the central amount equation gives

C(t)=\frac{F D k_a}{V(k_a-k_e)} \left(e^{-k_e t}-e^{-k_a t}\right).

If dose, absorption rate, and disposition parameters are held fixed, \(F\) appears only as a multiplicative factor. Changing \(F\) therefore scales concentration at every time by the same ratio. The concentration-time shape, including the time of peak concentration, remains unchanged. This conclusion also holds for a linear multi-compartment disposition model when the input profile is otherwise identical: multiplying the input by a constant multiplies the resulting concentrations by that constant.

This is a conditional result, not a claim that any two formulations with different bioavailability must have identical shapes. If their absorption rates or input profiles also differ, their shapes can differ as well. Bioavailability is an extent-of-input parameter; an absorption rate parameter describes the timing of input.

Worked Example: Scaling an Oral Concentration Profile

Consider a hypothetical 100 mg oral dose in a one-compartment model with \(V=20\) L, \(k_a=1.00\ \text{h}^{-1}\), and \(k_e=0.200\ \text{h}^{-1}\). Compare \(F=0.750\) with \(F=0.500\), holding all other parameters fixed. Find the predicted concentration at \(t=2.00\) h for \(F=0.750\), then determine the concentration for \(F=0.500\).

Substitute the first set of values into the concentration equation:

C(2)= \frac{(0.750)(100\ \text{mg})(1.00\ \text{h}^{-1})} {(20\ \text{L})(1.00-0.200)\ \text{h}^{-1}} \left(e^{-(0.200)(2.00)}-e^{-(1.00)(2.00)}\right).

The coefficient is \(75/16=4.6875\ \text{mg/L}\), and the exponential difference is \(e^{-0.400}-e^{-2.00}=0.6703-0.1353=0.5350\). Thus \(C(2)=4.6875(0.5350)=2.508\ \text{mg/L}\), to four significant figures.

The second bioavailability is \(0.500/0.750=2/3\) of the first. Therefore the concentration at 2.00 h is \((2/3)(2.508)=1.672\ \text{mg/L}\). The same two-thirds ratio applies at every time point. The lower \(F\) changes the concentration scale, not the curve's shape, because the model's absorption and disposition parameters were kept fixed.

Relative Bioavailability and Model Parameterization

An absolute comparison uses an IV reference, whose bioavailability is fixed at one. In a relative comparison, the reference is often another extravascular formulation. The ratio then represents how much dose-normalized exposure the test formulation produces relative to that reference. A ratio above one means greater dose-normalized exposure for the test condition under the model assumptions; it does not mean that more than 100% of the administered test dose reached the circulation.

Worked Example: Comparing Two Formulations

In a hypothetical linear-PK comparison, a 400 mg test formulation produces an AUC of 28 mg·h/L. A 500 mg reference formulation produces an AUC of 32 mg·h/L. Assume the same clearance for the formulations and complete AUC measurement. Calculate the relative bioavailability of test versus reference.

The test dose-normalized AUC is \(28/400=0.07000\ \text{h/L}\). The reference value is \(32/500=0.06400\ \text{h/L}\). Thus

F_{\mathrm{rel}}= \frac{0.07000\ \text{h/L}}{0.06400\ \text{h/L}} =1.094.

The test formulation has approximately 1.09 times the dose-normalized exposure of the reference, or about 9.38% greater exposure per milligram. This is a relative comparison. Without an IV reference, it does not establish either formulation's absolute bioavailability.

In a population model, bioavailability may be represented as a parameter that varies among individuals or conditions, while still acting on the systemic input. Absolute \(F\) should be constrained to a value from zero to one. A relative multiplier against a reference can exceed one. The interpretation depends on which parameterization is used; a relative multiplier should not be mistaken for an absolute fraction.

A further limitation is that oral concentration data alone may not identify absolute \(F\) and \(CL\) separately. The AUC relationship contains the ratio \(F/CL\). If \(F\) and \(CL\) are both multiplied by the same positive constant, that ratio is unchanged. Thus, without additional information or design features that distinguish them, oral exposure can support an apparent clearance parameter such as \(CL/F\) rather than independent estimates of absolute \(F\) and \(CL\). This is an identifiability issue, not evidence that the model's \(F\) parameter has been measured directly.

Assumptions, Diagnostics, and Common Pitfalls

The scaling and AUC results rely on assumptions that should be checked against the study design and observed data. In particular, the same disposition clearance must apply across the compared conditions, PK must be linear over the doses used, and the AUC must capture the relevant exposure. A model that changes \(F\) alone also assumes that the systemic input's timing and shape remain the same.

Dose-normalized concentration profiles provide a useful diagnostic. If conditions differ only by a constant bioavailability multiplier under linear PK, their dose-normalized profiles should have the same shape and differ by a constant scale. Systematic changes in peak timing or in the relative early and late profile may indicate that a change in \(F\) alone is insufficient. Such differences can also arise from sampling, measurement, or model misspecification, so a shape discrepancy is a diagnostic signal rather than proof of a particular mechanism.

The principal alternatives answer different questions. An explicit \(F\) parameter represents a fraction or relative input scale in the structural model. Dose-normalized AUC ratios estimate exposure comparisons without specifying the full concentration-time structure, but depend on their own design assumptions. Apparent parameters such as \(CL/F\) can describe oral data when absolute bioavailability is not separately known, but do not give an absolute clearance estimate unless \(F\) is known.

Mistake: “A lower \(F\) means absorption is slower.” Correction: \(F\) scales the amount reaching systemic circulation. A slower input requires a change in the absorption-time structure or its rate parameters.
Mistake: “The relative bioavailability is 1.094, so 109.4% of the dose reached the circulation.” Correction: 1.094 is a ratio to a reference formulation; it is not an absolute fraction.
Mistake: “The AUC ratio directly identifies absolute \(F\) even when clearance differs.” Correction: the ratio isolates \(F\) only when the compared conditions share clearance and the other assumptions for the AUC comparison hold.

Key takeaway: In a linear structural model, bioavailability multiplies systemic input. With the same input timing and disposition, it changes exposure by a constant factor without changing concentration-time shape. Absolute and relative interpretations depend on the reference and on the assumptions supporting the comparison.

Check Your Understanding

Answer each question, then compare your reasoning with the solutions below.

A 250 mg IV dose gives an AUC of 20 mg·h/L. A 500 mg oral dose gives an AUC of 30 mg·h/L. Under the assumptions for an absolute comparison, what is oral \(F\)?
If \(F\) changes from 0.40 to 0.80 while dose, absorption rate, and disposition are fixed in a linear model, what happens to each concentration at a given time?
A test formulation has a dose-normalized AUC of 0.090 h/L, and its reference has 0.100 h/L. What is the relative bioavailability of test versus reference?
Why can oral AUC data alone fail to distinguish absolute \(F\) from \(CL\)?

Solutions. (1) The dose-normalized IV AUC is \(20/250=0.08000\ \text{h/L}\), and the oral value is \(30/500=0.06000\ \text{h/L}\). Therefore \(F=0.06000/0.08000=0.750\), or 75.0%, assuming shared clearance, linear PK, and complete AUCs. (2) The bioavailability doubles, so every predicted concentration doubles; the shape is unchanged if all other model features remain fixed. (3) \(F_{\mathrm{rel}}=0.090/0.100=0.900\). The test formulation has 90.0% of the reference's dose-normalized exposure, not an absolute bioavailability of 90.0%. (4) Oral AUC depends on \(F/CL\), since \(AUC=FD/CL\). Without other information, different combinations of \(F\) and \(CL\) can produce the same AUC.